drugset / Trial / NCT05055518
APL-102 Capsule in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.
Timeline
- Start
- 2021-08-02
- Primary completion
- 2028-10-31
- Completion
- 2028-12-31
Outcome
Outcome not reported
Stopped (Business): “Voluntarily suspended (due to adjustments in corporate development strategy, not for reasons related to safety or efficacy.)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APL-102 | Unknown | 1 mg | — |
| Subject | APL-102 | Unknown | 2 mg | — |
| Subject | APL-102 | Unknown | 3 mg | — |
| Subject | APL-102 | Unknown | 5 mg | — |
| Subject | APL-102 | Unknown | 7 mg | — |
| Subject | APL-102 | Unknown | 9 mg | — |
| Subject | APL-102 | Unknown | 11 mg | — |
Indications
No indication recorded.